Products for Research Use Only

SB-284851-BT

CAT: 0804-HY-136794Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-136794Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SB-284851-BT is an inhibitor of BRD4/p38α/BRDT. SB-284851-BT inhibits BRD4-BD1 (IC50=1.7 µM), p38α (Kd=0.47 nM), BRDT (1) (IC50=18 µM) and BRD4 (1) (IC50=3.7 µM) . SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET) [1][2].
CAS Number
219769-23-0
UNSPSC
12352005
Target
Epigenetic Reader Domain; p38 MAPK
Type
Reference compound
Related Pathways
Epigenetics; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sb-284851-bt.html
Solubility
10 mM in DMSO
Smiles
FC1=CC=C(C2=C(C3=NC(OC4=CC(C)=CC(C)=C4)=NC=C3)N(C5CCNCC5)C=N2)C=C1
Molecular Formula
C26H26FN5O
Molecular Weight
443.52
References & Citations
[1]Divakaran A, et al. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem. 2018 Oct 25;61 (20) :9316-9334. |[2]Jin W, et al. Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions. Drug Discov Today. 2022 Jan;27 (1) :246-256.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4; BRDT; p38α

Popular Products